Add like
Add dislike
Add to saved papers

Lack of cross-resistance between neonicotinoids and sulfoxaflor in field strains of Q-biotype of whitefly, Bemisia tabaci, from eastern China.

Control of Bemisia tabaci has depended primarily and heavily on insecticides, especially neonicotinoids. The novel sulfoximine insecticide sulfoxaflor exhibits high potency against a broad range of sap-feeding insect species, including those resistant to neonicotinoids. The resistance levels of Q-biotype B. tabaci field strains collected from 8 locations in eastern China to neonicotinoids and sulfoxaflor were investigated, and single nucleotide polymorphisms (SNPs) of nicotinic acetylcholine receptor β1 subunit gene (Btβ1) were detected. Compared with the reference strain, the field strains had developed low to moderate levels of resistance to imidacloprid and nitenpyram with the resistance ratios (RR) ranging between 4.07 and 21.75-fold and 3.37 and 16.14-fold, respectively. While YZ strain exhibited high resistance (RF 40.38) to thiamethoxam, only low levels of resistance to thiamethoxam (RF 3.50-8.58) was observed in other strains. All strains were relatively susceptible to both dinotefuran (RF 0.50-2.55) and sulfoxaflor (RF 0.40-3.07). Sequence analysis of Btβ1 cDNA fragments revealed 23 SNPs representing 19 amino acid replacements in these strains. Notably, a 45bp fragment deletion was detected in JY strain, which encodes 15 amino acid residues (positions 66-80) containing arginine at position 79 (R79) corresponding to the R81T mutation in Loop D of nAChR β1 subunit in Myzus persicae resistant to neonicotinoids. The lack of cross-resistance indicates that both dinotefuran and sulfoxaflor could play an important role in the control of B. tabaci already resistant to the first and second generation neonicotinoids.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app